Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four-month clinical trial

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 5 II, 1999, Pages

  Young, R L ^a   Delconte, A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ethinyl estradiol; Levonorgestrel; Lipid; Oral contraceptive

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032753171     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9378(99)70365-0     Document Type: Article

References (14)

1. K Brill A Then U Beisiegel A Jene C Wünsch F Leidenberger Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial Contraception 54 1996 291 297
2. M Akerlund E Almström S Högstedt M Nabrink Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel: their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone Acta Obstet Gynecol Scand 73 1994 136 143
3. DF Archer R Maheux A DelConte FB O’Brien A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms North American Levonorgestrel Study Group (NALSG) Contraception 55 1997 139 144
4. U Larsson-Cohn L Wallentin G Zador Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel Horm Metab Res 11 1979 437 440
5. G Samsioe Comparative effects of the oral contraceptive combinations 0.150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers Contraception 25 1982 487 502
6. WHO HRP Task Force on Oral Contraceptives A randomized double-blind study of the effects of two low-dose combined oral contraceptives on biochemical aspects: report from a seven-centred study WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task force on Oral Contraceptives Contraception 32 1985 223 236
7. G Coata F Ventura R Lombardini G Ciuffetti EV Cosmi GC Di Renzo Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism Contraception 52 1995 151 157
8. A Teichmann Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel Int J Fertil Menopausal Stud 40 suppl 2 1995 98 104
9. RT Burkmann JC Robinson D Kruszon-Moran AW Kimball P Kwiterovich RG Burford Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial Obstet Gynecol 71 1988 33 38
10. MG Powell AM Hedlin I Cerskus G Kakis D Prudham P Rosenrot Effects of oral contraceptives on lipoprotein lipids: a prospective study Obstet Gynecol 63 1984 764 770
11. SL Corson Efficacy and clinical profile of a new oral contraceptive containing norgestimate: US clinical trials Acta Obstet Gynecol Scand Suppl 152 1990 25 31
12. G Kakis M Powell A Marshall TB Woutersz G Steiner A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids Int J Fertil Menopausal Stud 39 1994 283 291
13. MJ Stampfer WC Willett GA Colditz FE Speizer CH Hennekens Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses’ Health Study Am J Obstet Gynecol 163 1 Pt 2 1990 285 291
14. P Croft PC Hannaford Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study BMJ 298 1989 165 168